TABLE 1.
Characteristics of patients corresponding to each tumorgraft line.
| XPID | Race | Age | Sex | Source | Histology | Sarcomatoid | Rhabdoid | Nucleolar Grade | Stage | Prior Therapy |
|---|---|---|---|---|---|---|---|---|---|---|
| XP165 | White | 42 | Male | Abdominal mass | ccRCC | NA | NA | 3 | - | HD-IL2, Interferon, Bevacizumab |
| XP283 | White | 77 | Female | Kidney | ccRCC | Absent | NA | 3 | T3aN0M0 | Treatment Naïve |
| XP289 | White | 62 | Female | Kidney | ccRCC | Absent | NA | 3 | T3aN0M1 | Treatment Naïve |
| XP374 | White | 48 | Male | Kidney | ccRCC | Present | Present | 4 | T4N0M0 | Treatment Naïve |
| XP1487 * | White | 70 | Female | Lymph node | ccRCC | Absent | Absent | 3 | - | Sunitinib, Nivolumab, Axitinib, ARO-HIF2 |
*
TG line from tumor biopsy of phase I trial participant. NA, not available.